Tamoxifen, widely used in cases of hormone receptor-positive breast cancer, ductal carcinoma in situ (DCIS), and those at high risk of breast cancer (8, 9), is known to have a protective effect on bone health in postmenopausal women. The gene discussed is NR4A1; the disease is ductal breast carcinoma in situ.